Abstract：
The aim of this collaborative document is to provide an update for clinicians on best antithrombotic strategies in patients with aortic and/or peripheral arterial diseases. Antithrombotic therapy is a pillar of optimal medical treatment for these patients at very high cardiovascular risk. While the number of trials on antithrombotic therapies in patients with aortic or peripheral arterial diseases is substantially smaller than for those with coronary artery disease, recent evidence deserves to be incorporated into clinical practice. In the absence of specific indications for chronic oral anticoagulation due to concomitant cardiovascular disease, a single antiplatelet agent is the basis for long-term antithrombotic treatment in patients with aortic or peripheral arterial diseases. Its association with another antiplatelet agent or low-dose anticoagulants will be discussed, based on patient\'s ischaemic and bleeding risk as well therapeutic paths (e.g. endovascular therapy). This consensus document aims to provide a guidance for antithrombotic therapy according to arterial disease localizations and clinical presentation. However, it cannot substitute multidisciplinary team discussions, which are particularly important in patients with uncertain ischaemic/bleeding balance. Importantly, since this balance evolves over time in an individual patient, a regular reassessment of the antithrombotic therapy is of paramount importance.
摘要：
本合作文件的目的是为临床医生提供主动脉和/或外周动脉疾病患者最佳抗血栓策略的最新信息。抗血栓治疗是这些心血管风险非常高的患者的最佳药物治疗的支柱。虽然主动脉或外周动脉疾病患者的抗血栓治疗试验数量明显少于冠状动脉疾病患者，最近的证据值得纳入临床实践。在没有特定适应症的慢性口服抗凝伴随心血管疾病，单一抗血小板药物是主动脉或外周动脉疾病患者长期抗血栓治疗的基础.将讨论其与另一种抗血小板药或低剂量抗凝剂的关联，根据患者的缺血和出血风险以及治疗路径（例如血管内治疗）。该共识文件旨在根据动脉疾病的定位和临床表现为抗血栓治疗提供指导。然而,它不能取代多学科团队的讨论，这在缺血/出血平衡不确定的患者中尤为重要。重要的是,因为这种平衡在个体患者中随着时间的推移而发展，定期重新评估抗血栓治疗至关重要.
